Showing 4251-4260 of 7593 results for "".
- FDA Approves Cosentyx Label Update to Include Scalp Psoriasishttps://practicaldermatology.com/news/fda-approves-cosentyx-label-update-to-include-scalp-psoriasis/2457896/The FDA has approved a label update for Novartis' Cosentyx (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis. The updated label includes Cosentyx data in moderate to severe scalp psoriasis—one of the difficult-to-treat for
- Research Finds Acne Linked with Increased Risk of Depressionhttps://practicaldermatology.com/news/research-finds-acne-linked-with-increased-risk-of-depression/2457898/In an analysis of one of the largest electronic medical records databases in the world, researchers found that patients with acne had a significantly increased risk of developing major depression, but only in the first 5 years after being diagnosed with acne.
- eRelevance Adds Two to Executive Leadership Teamhttps://practicaldermatology.com/news/erelevance-adds-two-to-executive-leadership-team/2457901/eRelevance has added two new names to its executive leadership team. Rafael Landestoy is now vice president of business development and Travis Skidmore is vice president of client success and retention. Mr. Landestoy will lead eRelevance&nbs
- Allergan Rolls Out "Not Cool vs. Cool"CoolSculpting Campaign Starring Professional Male Athlete Brand Ambassadorshttps://practicaldermatology.com/news/allergan-rolls-out-not-cool-vs-coolcoolsculpting-campaign-starring-professional-male-athlete-brand-ambassadors/2457905/Allergan’s new "Not Cool vs. Cool" Multi-Channel Campaign for CoolSculpting® stars Professional Athlete Brand Ambassadors: Figure Skater Johnny Weir and Go
- Apple Update Brings Healthcare Records to Phoneshttps://practicaldermatology.com/news/apple-update-brings-healthcare-records-to-phones/2457906/Apple has introduced a significant update to the Health app with the iOS 11.3 beta introducing a feature that gives customers access to their medical records on their iPhone. The updated H
- Amazon, Berkshire Hathaway, JPMorgan Chase Partner on Healthcarehttps://practicaldermatology.com/news/amazon-berkshire-hathaway-jpmorgan-chase-partner-on-healthcare/2457907/Amazon, Berkshire Hathaway, and JPMorgan Chase & Co. are partnering in an effort to seek solutions for delivering healthcare to their employees. The three companies will pursue this objective through an independent company that is free from profit-making incentives and constraints, they said
- Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in EBhttps://practicaldermatology.com/news/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-eb/2457908/The US Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, Abeona Therapeutics Inc.’s gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB). “EB-101 is
- Intraderm Changes Alevicyn Product Name to Levicynhttps://practicaldermatology.com/news/intraderm-changes-alevicyn-product-name-to-levicyn/2457910/Intraderm's Alevicyn is getting a new name—Levicyn. The Gel formulation is now Levicyn Antipruritic Gel, the Spray Gel is now Levicyn Antipruritic SG, and the Dermal Spray is now Levicyn Antimicrobial Dermal Spray. The company notes that physicians can still write for Alevicyn d
- Alastin Skincare Launches Restorative Neck Complexhttps://practicaldermatology.com/news/alastin-skincare-launches-restorative-neck-complex/2457916/Alastin Skincare, Inc. has incorporated its proven, proprietary TriHex Technology into a new product designed for the specific needs of the neck and décolletage: Restorative Neck Complexwith TriHex Technology. This breakthrough treatment is formulated to addr
- Anti-IL22 Therapy May Represent New Treatment Option for Severe ADhttps://practicaldermatology.com/news/researchers-close-in-on-possible-new-treatment-for-severe-ad/2457913/New research suggests that IL-22/Th22 targeting may offer a novel treatment alternative for patients with severe atopic dermatitis (AD). The findings, which appear in the Journal of the American Academy of Dermatology, provide the first e